Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug YL202 targets Hard-to-Treat breast cancers

NCT ID NCT06439771

Recruiting now Disease control Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This phase 2 trial tests an experimental drug called YL202 in people with advanced or metastatic breast cancer that has not responded to other treatments. The study includes patients with triple-negative breast cancer (TNBC) or hormone receptor-positive, HER2-zero or HER2-low tumors. Researchers aim to see how well YL202 shrinks tumors and to check its safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental antibody-drug conjugate called YL202
What this could lead to
If successful, YL202 could offer a new treatment option for people with advanced breast cancers that have limited effective therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not confirm effectiveness. The drug may cause side effects or fail to shrink tumors in many patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED OR METASTATIC BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, 250117, China

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.